Debasis Sahoo, MD
Pulmonary Disease · Cleveland, OHNPI 1376701458
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.8%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Sanofi at 48.8% of the total. 2025 is the largest year on record at $7,126, 2.1 times the $3,345 reported in 2019.
Across 271 payments — averaging $69.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$9K
- Boehringer Ingelheim$3K
- Regeneron Healthcare Solutions, Inc.$3K
- GSK$1K
- Amgen$317
- AstraZeneca$298
- plus $2K from 22 others
Across 20 payments — averaging $4020.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mallinckrodt Enterprises LLC$55K
- Mallinckrodt Hospital Products Inc.$26K
What the payments were for
- Consulting fees$4,11222%
- Speaking & faculty fees$9,12849%
- Travel & lodging$190%
- Food & beverage$5,21628%
- Education$2291%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 44 | $9,130 |
| Boehringer Ingelheim | 4 | $3,103 |
| Regeneron Healthcare Solutions, Inc. | 14 | $2,551 |
| GSK | 100 | $1,357 |
| Amgen | 13 | $317 |
| AstraZeneca | 16 | $298 |
| United Therapeutics Corporation | 13 | $258 |
| Baxter Healthcare | 10 | $256 |
| Merck | 8 | $194 |
| Insmed, Inc. | 8 | $181 |
| Actelion Pharmaceuticals US, Inc. | 4 | $145 |
| Teva Pharmaceuticals USA, Inc. | 9 | $143 |
| Genentech USA, Inc. | 1 | $137 |
| Mallinckrodt Enterprises LLC | 1 | $90 |
| Advanced Respiratory, Inc | 5 | $88 |
| Averitas Pharma Inc. | 3 | $73 |
| AbbVie | 4 | $69 |
| Sanofi-aventis U.S. LLC | 1 | $60 |
| GRT US Holding, Inc. | 3 | $55 |
| Mylan Specialty L.p. | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Pfizer | 1 | $23 |
| Abbott | 1 | $21 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Viatris Specialty LLC | 1 | $17 |
| Inogen, Inc. | 1 | $16 |
| Z-medica, LLC | 1 | $15 |
| Vertex | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,703 in reported general payments places this provider in the 85th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 24 | $243,540 |
| OfevNintedanib Esylate | 18 | $214,772 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 143 | $116,501 |
| XolairOmalizumab | 13 | $95,539 |
| EsbrietPirfenidone | 13 | $89,109 |
| Breo ElliptaFluticasone/Vilanterol | 110 | $54,113 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 56 | $50,554 |
| TezspireTezepelumab-Ekko | 11 | $42,930 |
| Pirfenidone | 29 | $37,526 |
| EliquisApixaban | 32 | $31,417 |
| Spiriva RespimatTiotropium Bromide | 44 | $26,922 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 45 | $24,404 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $19,108 |
| Spiriva HandihalerTiotropium Bromide | 20 | $16,065 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 97 | $10,793 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $3,103 | $266,098107 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $1,357 | $203,129321 claims |
| AstraZenecaBreztri Aerosphere, Tezspire, Symbicort | $298 | $96,01378 claims |
| Genentech USA, Inc.Esbriet | $137 | $89,10913 claims |
| PfizerEliquis | $23 | $31,41732 claims |
| MerckDulera | $194 | $4,48613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Cleveland
- Kristin HighlandCleveland$551K
- Joseph CiceniaCleveland$350K
- Michael MachuzakCleveland$286K
- Marie BudevCleveland$159K
- Leslie TolleCleveland$136K
- Elliott DasenbrookCleveland$114K
- James StollerCleveland$101K
- Gustavo Heresi DavilaCleveland$98K
- Bryan BennCleveland$96K
- Thomas GildeaCleveland$69K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.